NCT03144583已完成1 期
Pilot Study on the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity Conjugated With the Co-stimulatory Regions 4-1BB and CD3z in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
Sara V. Latorre4 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2017年6月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 4
- 主要终点
- Procedure-related mortality (PRM)
研究概览
简要总结
To assess the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity [A3B1] conjugated with the co-stimulatory regions 4-1BB and CD3z ) safety on patients with leukemia or lymphoma CD19+ resistant or refractory to treatment and with a prognosis of less than 2 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
盲法说明
Open label
入排标准
- 年龄范围
- 2 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of leukemia or CD19 + lymphoma, with a life expectancy less than 2 years that meet the following conditions:- Adult acute lymphoid leukemia in second or third response, not candidate for transplantation due to age, associated diseases or lack of donor, or in relapse post allogeneic transplant.- Pediatric acute lymphoid leukemia in second or third response, refractory or non-transplant candidate due to donor absence, or in relapse post allogeneic transplant, or with minimal residual residual disease (0.1% or greater) after two or more lines of treatment. - Symptomatic follicular lymphoma, which has received at least 2 treatment regimens (one of them including rituximab) and a progression-free interval of less than 2 years. Patients not candidates for transplantation or post-transplant relapse may be included.- Symptomatic chronic lymphocytic leukemia, which has received at least 2 treatment regimens (one of them including rituximab) and a progression-free survival of less than 2 years. Patients with a 17p deletion or TP53 mutation may be included after the first line of treatment. - Mantle cell lymphoma in the first relapse (or higher) when it is not a candidate for transplantation, or second post-transplant relapse (or higher). - Diffuse large cell lymphoma in first relapse (or higher) when it is not a candidate for transplantation, or second post-transplant relapse (or higher).
- •Age greater than 2 years and less than
- •ECOG functional status from 0 to 2
- •Life expectancy of at least 3 months.
- •Appropriate venous access to perform an apheresis procedure. Absence of contraindications for it.
- •Signature of informed consent (patient or legal guardian).
排除标准
- •Treatment with any experimental or non-marketed substance within four weeks prior to recruitment, or actively participating in another therapeutic clinical trial.
- •Diagnosis of another past or present neoplasm. Patients may be included in complete remission for more than 3 years, or with a history of non-melanoma skin cancer or completely resected in-situ carcinoma.
- •Central nervous system involvement (CNS-3) at inclusion. Inclusion will be permitted with patients with a lower grade (CNS-2) or with CNS-3 who have responded to intrathecal chemotherapy.
- •Early relapse after allogeneic transplantation (less than 3 months for apheresis of mononuclear cells, less than 6 months for infusion of ARI-0001) or patients on active immunosuppressive therapy for graft-versus-host disease (corticosteroids or other systemic immunosuppressants ).
- •Active infection requiring systemic medical treatment such as chronic kidney infection, chronic lung infection or tuberculosis.
- •HIV infection.
- •Concurrent and uncontrolled medical illnesses including cardiac, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological or psychiatric diseases which in the opinion of the researcher represent a risk to the patient.
- •Positive serology for hepatitis B, defined as a positive test for HBsAg. In addition, if the patient is HBsAg negative but has anti-HBc antibodies it will be necessary to perform a DNA test of the hepatitis B virus, and if the result is positive the patient will be excluded.
- •Positive serology for hepatitis C, defined as a positive test for anti-HCV antibodies confirmed by RIBA.
- •Severe organ failure, defined as a cardiac ejection fraction <40%; DLCO <40%; calculated glomerular filtrate rate <30 ml / min; Or bilirubin> 3 times the upper limit of normal (unless it is due to CLL or Gilbert syndrome).
- •Pregnant or lactating women. Women of childbearing potential should have a negative pregnancy test in the screening phase.
- •Women of childbearing age, including those whose last menstrual cycle was in the year prior to screening, who are unable or unwilling to use highly effective contraceptive methods from the start of the study to the end of the study.
- •Men who are unable or unwilling to use highly effective contraceptive methods from the start of the study to the completion of the study.
- •The need to take glucocorticoids in a chronic manner at doses higher than 10 mg / day of prednisone (or equivalent) or other chronic immunosuppressants. Hormonal contraceptives, intrauterine device, intrauterine systems of hormonal release, sexual abstinence, vasectomy of the couple or bilateral tubal occlusion.
结局指标
主要结局
Procedure-related mortality (PRM)
时间窗: Year 3
Any death not caused directly by leukemia / lymphoma. For the estimation of PRM, relapse or progression of the disease will be considered as a competitive event.
Assessment of toxicity
时间窗: Year 1
number of adverse events grade III-IV using CTC (common toxicity criteria)
次要结局
- In vivo survival of ARI-0001 cells in peripheral blood, bone marrow and cerebrospinal fluid(months 9,12,15,18,21,24)
- Toxicity assessment(Month 3 and year 1)
- Response rate (overall and complete)(Month 3 and Year 1)
- Progression-free survival(Year 2 after procedure)
- Overall survival (OS) at 2 years(3 years)
- Quality of life of included patients(Month 3, 6, 12)
研究者
Sara V. Latorre
Clinical Research Manager
Institut d'Investigacions Biomèdiques August Pi i Sunyer
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)Prostate CancerNCT01140373Memorial Sloan Kettering Cancer Center13
已完成
1 期
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to ChemotherapyHematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRefractory Chronic Lymphocytic LeukemiaStage III Adult Diffuse Large Cell LymphomaStage III Chronic Lymphocytic LeukemiaStage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage III Grade 3 Follicular LymphomaStage III Mantle Cell LymphomaStage IV Adult Diffuse Large Cell LymphomaStage IV Chronic Lymphocytic LeukemiaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular LymphomaStage IV Mantle Cell LymphomaProlymphocytic LeukemiaNCT01029366University of Pennsylvania26
终止
早期 1 期
CD19 Redirected Autologous T Cells for Hodgkin LymphomaHodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited PrognosisNCT02277522University of Pennsylvania4
Unknown
不适用
Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic AdenocarcinomaAdvanced Gastric AdenocarcinomaPancreatic AdenocarcinomaNCT03159819Changhai Hospital24
Unknown
不适用
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsB Cell LymphomaB Cell LeukemiaMyelomaPancreatic CarcinomaAdenocarcinoma of Esophagogastric JunctionHepatocellular CarcinomaNCT03302403Kang YU18